If you only glanced at Ionis Pharmaceuticals’ headlines this year, a string of FDA approvals, upbeat trial readouts, and higher revenue might look like a winning hand. Investors who held Ionis Pharmaceuticals from the start of the year are down 64.8%, including dividends. If you had been weighing a fresh position back on 1 January 2026, what in the record then hinted that such a hit to capital was even on the table?
Ionis Pharmaceuticals has already moved. Pinpoint other ways to investigate the theme among 36 healthcare AI stocks.
The shares cost US$79.11 at the start, and Ionis Pharmaceuticals sat between two sharply different stories about what might happen next.
The bullish camp saw a commercial engine finally clicking. Its Fair Value of US$96, a price implied by optimistic forecasts, rested on assumptions of 27.7% annual revenue growth and profit margins rising to 19.0% within about three years.
The more cautious view put Fair Value at US$69.48, again an implied price, and focused on risks that expanding Olezarsen into broader sHTG use could pressure pricing and limit future margin progress.
Ionis Pharmaceuticals won FDA approval for Tryngolza in broader severe hypertriglyceridemia, which backed the bullish focus on label expansion and sHTG demand. Q3 2026 also showed revenue higher at US$242.7m versus US$156.7m a year earlier, while the group still reported a loss of US$110.0m and a net margin of 45.3% in the red. The period cut both ways.
The key assumption investors priced was not just growth but the path to profit. For another biotech, you would stress test that same claim by tracking how quickly rising sales narrow losses and lift net margin toward the level analysts once baked into their Fair Value math.
Today the Ionis Pharmaceuticals share price is US$28.01, which is far below where it started the year. The bullish analyst Narrative on Simply Wall St still places its Fair Value above that level, built on a view that recent approvals and late stage results can support a larger commercial footprint.
The core bet is that Ionis converts Tryngolza, DAWNZERA, ZANVASTRO and newer neurology and renal programs into sustained adoption and reimbursement that eventually shift the business from losses to durable profitability.
"The current numbers around multibillion dollar Tryngolza peak sales targets, reaffirmed 2026 revenue guidance and removal of some partnered milestones from models imply a share price that does not fully reflect potential upside from the APOC3 franchise and the emerging neurology and renal royalty streams."
One Narrative disagrees with today's price. → See where this Narrative says Ionis Pharmaceuticals should trade
The next headline does not have to be where your research begins. Go straight to the companies and see whether a contrarian opportunity could be taking shape.
That is three of the list. See all 35 potentially undervalued companies →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com